Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

FATE

FATE News

Newswire

11:48

Fate Therapeutics Q3 Earnings Beat Estimates, Revenue Surges 104.82%

08:38

Fate Therapeutics reports Q3 2025 financial results, receives UK and EU trial authorization.

06:25

HC Wainwright Upgrades Fate Therapeutics to 'Buy', Maintains $5.00 Price Target

13:57

Fate Therapeutics (FATE) Gets Upgrade to Buy from HC Wainwright & Co.

07:03

Fate Therapeutics: HC Wainwright Upgrades Buy to Neutral, PT Raised to $5.00.

View More

About FATE

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More